376 related articles for article (PubMed ID: 27211273)
1. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
[TBL] [Abstract][Full Text] [Related]
2. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome.
Clough CA; Pangallo J; Sarchi M; Ilagan JO; North K; Bergantinos R; Stolla MC; Naru J; Nugent P; Kim E; Stirewalt DL; Subramaniam AR; Abdel-Wahab O; Abkowitz JL; Bradley RK; Doulatov S
Blood; 2022 Mar; 139(13):2038-2049. PubMed ID: 34861039
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
4. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
[TBL] [Abstract][Full Text] [Related]
5. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.
Ochi T; Fujiwara T; Ono K; Suzuki C; Nikaido M; Inoue D; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Nakamura Y; Harigae H
Sci Rep; 2022 Aug; 12(1):14562. PubMed ID: 36028755
[TBL] [Abstract][Full Text] [Related]
6. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
7. A variant erythroferrone disrupts iron homeostasis in
Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
[TBL] [Abstract][Full Text] [Related]
8. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
[TBL] [Abstract][Full Text] [Related]
9.
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
Malcovati L; Cazzola M
Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
[TBL] [Abstract][Full Text] [Related]
11. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
13. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
[TBL] [Abstract][Full Text] [Related]
14. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
15. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts.
Adema V; Ma F; Kanagal-Shamanna R; Thongon N; Montalban-Bravo G; Yang H; Peslak SA; Wang F; Acha P; Sole F; Lockyer P; Cassari M; Maciejewski JP; Visconte V; Gañán-Gómez I; Song Y; Bueso-Ramos C; Pellegrini M; Tan TM; Bejar R; Carew JS; Halene S; Santini V; Al-Atrash G; Clise-Dwyer K; Garcia-Manero G; Blobel GA; Colla S
Blood Cancer Discov; 2022 Nov; 3(6):554-567. PubMed ID: 35926182
[TBL] [Abstract][Full Text] [Related]
16. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
17. The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts.
Ma L; Luo Y; Jiang L; Shen D; Li J; Xu W; Mei C; Zhou X; Ren Y; Ye L; Lu C; Jie J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1179-1186. PubMed ID: 30409066
[TBL] [Abstract][Full Text] [Related]
18. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.
Visconte V; Avishai N; Mahfouz R; Tabarroki A; Cowen J; Sharghi-Moshtaghin R; Hitomi M; Rogers HJ; Hasrouni E; Phillips J; Sekeres MA; Heuer AH; Saunthararajah Y; Barnard J; Tiu RV
Leukemia; 2015 Jan; 29(1):188-95. PubMed ID: 24854990
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
[TBL] [Abstract][Full Text] [Related]
20. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]